Medical News

Study Looks at Efficacy, Cardiovascular Risks of Two HIV Treatments

July 20, 2009

Patients taking Boehringer Ingelheim's HIV drug Viramune have a lower risk of developing cardiovascular disease than those taking Bristol-Myers Squibb's treatment, Reyataz, according to a study released on Monday at the 5th International AIDS Society conference in Cape Town, South Africa, Reuters reports. "The drug trial, involving 569 participants, yielded that Viramune, while being as effective at suppressing HIV as Bristol Myers' blockbuster Reyataz, had a more favourable effect on patients' cardiovascular risks, as measured by certain blood lipids," the article states. The study found that "Viramune-treated patients ... had more than twice the level of HDL cholesterol, known as 'good cholesterol' for its beneficial effect on blood vessels, than those on Reyataz, Boehringer said in a statement," Reuters reports. The article adds that advances in antiretroviral drugs have helped make HIV a "treatable chronic condition," and "as a result, patients are growing older, bringing other symptoms of an HIV infection, such as cardiovascular diseases, to the fore" (Burger, Reuters, 7/20).

Back to other news for July 2009

This information was reprinted from with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily U.S. HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.